Ezetimibe inhibits lymphatic transport of esterified cholesterol but not free cholesterol in thoracic lymph duct-cannulated rats

Bungo Shirouchi, Yuri Nakamura, Yumiko Furukawa, Aya Shiraishi, Hiroko Tomoyori, Katsumi Imaizumi, Masao Sato

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose Ezetimibe has been shown to inhibit dietary cholesterol absorption in animal models and humans, but studies on lymphatic lipid transport have not yet been performed. Rats subjected to permanent lymph duct cannulation were used to investigate the effects of ezetimibe on lipid transport. Methods Rats were fed diets with and without ezetimibe (5.0 mg/kg), and their lymph was collected after feeding to quantify lymphatic lipid levels. Total cholesterol content in the intestinal mucosa was also measured. Results Rats that consumed ezetimibe had significantly lower lymphatic total cholesterol transport with the reduction of esterified cholesterol transport. According to the calculation based on cholesterol consumption, ezetimibe reduced the total cholesterol lymphatic recovery rate by 54 %. We also determined that ezetimibe significantly reduced the total cholesterol content in the intestinal mucosa. Conclusion This is the first direct evidence that ezetimibe inhibits esterified but not free cholesterol lymphatic transport in thoracic duct-cannulated rats. The results also indicate that ezetimibe is not involved in the lymphatic transport of triacylglycerols, phospholipids, or a-tocopherol.

Original languageEnglish
Pages (from-to)427-431
Number of pages5
JournalCardiovascular Drugs and Therapy
Volume26
Issue number5
DOIs
Publication statusPublished - Oct 1 2012

Fingerprint

Thoracic Duct
Lymph
Cholesterol
Intestinal Mucosa
Lipids
Dietary Cholesterol
Tocopherols
Ezetimibe
Catheterization
Phospholipids
Triglycerides
Animal Models
Diet

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Ezetimibe inhibits lymphatic transport of esterified cholesterol but not free cholesterol in thoracic lymph duct-cannulated rats. / Shirouchi, Bungo; Nakamura, Yuri; Furukawa, Yumiko; Shiraishi, Aya; Tomoyori, Hiroko; Imaizumi, Katsumi; Sato, Masao.

In: Cardiovascular Drugs and Therapy, Vol. 26, No. 5, 01.10.2012, p. 427-431.

Research output: Contribution to journalArticle

Shirouchi, Bungo ; Nakamura, Yuri ; Furukawa, Yumiko ; Shiraishi, Aya ; Tomoyori, Hiroko ; Imaizumi, Katsumi ; Sato, Masao. / Ezetimibe inhibits lymphatic transport of esterified cholesterol but not free cholesterol in thoracic lymph duct-cannulated rats. In: Cardiovascular Drugs and Therapy. 2012 ; Vol. 26, No. 5. pp. 427-431.
@article{bc1d6eb2d37a4a638b2bd47830b55d20,
title = "Ezetimibe inhibits lymphatic transport of esterified cholesterol but not free cholesterol in thoracic lymph duct-cannulated rats",
abstract = "Purpose Ezetimibe has been shown to inhibit dietary cholesterol absorption in animal models and humans, but studies on lymphatic lipid transport have not yet been performed. Rats subjected to permanent lymph duct cannulation were used to investigate the effects of ezetimibe on lipid transport. Methods Rats were fed diets with and without ezetimibe (5.0 mg/kg), and their lymph was collected after feeding to quantify lymphatic lipid levels. Total cholesterol content in the intestinal mucosa was also measured. Results Rats that consumed ezetimibe had significantly lower lymphatic total cholesterol transport with the reduction of esterified cholesterol transport. According to the calculation based on cholesterol consumption, ezetimibe reduced the total cholesterol lymphatic recovery rate by 54 {\%}. We also determined that ezetimibe significantly reduced the total cholesterol content in the intestinal mucosa. Conclusion This is the first direct evidence that ezetimibe inhibits esterified but not free cholesterol lymphatic transport in thoracic duct-cannulated rats. The results also indicate that ezetimibe is not involved in the lymphatic transport of triacylglycerols, phospholipids, or a-tocopherol.",
author = "Bungo Shirouchi and Yuri Nakamura and Yumiko Furukawa and Aya Shiraishi and Hiroko Tomoyori and Katsumi Imaizumi and Masao Sato",
year = "2012",
month = "10",
day = "1",
doi = "10.1007/s10557-012-6403-3",
language = "English",
volume = "26",
pages = "427--431",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "5",

}

TY - JOUR

T1 - Ezetimibe inhibits lymphatic transport of esterified cholesterol but not free cholesterol in thoracic lymph duct-cannulated rats

AU - Shirouchi, Bungo

AU - Nakamura, Yuri

AU - Furukawa, Yumiko

AU - Shiraishi, Aya

AU - Tomoyori, Hiroko

AU - Imaizumi, Katsumi

AU - Sato, Masao

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Purpose Ezetimibe has been shown to inhibit dietary cholesterol absorption in animal models and humans, but studies on lymphatic lipid transport have not yet been performed. Rats subjected to permanent lymph duct cannulation were used to investigate the effects of ezetimibe on lipid transport. Methods Rats were fed diets with and without ezetimibe (5.0 mg/kg), and their lymph was collected after feeding to quantify lymphatic lipid levels. Total cholesterol content in the intestinal mucosa was also measured. Results Rats that consumed ezetimibe had significantly lower lymphatic total cholesterol transport with the reduction of esterified cholesterol transport. According to the calculation based on cholesterol consumption, ezetimibe reduced the total cholesterol lymphatic recovery rate by 54 %. We also determined that ezetimibe significantly reduced the total cholesterol content in the intestinal mucosa. Conclusion This is the first direct evidence that ezetimibe inhibits esterified but not free cholesterol lymphatic transport in thoracic duct-cannulated rats. The results also indicate that ezetimibe is not involved in the lymphatic transport of triacylglycerols, phospholipids, or a-tocopherol.

AB - Purpose Ezetimibe has been shown to inhibit dietary cholesterol absorption in animal models and humans, but studies on lymphatic lipid transport have not yet been performed. Rats subjected to permanent lymph duct cannulation were used to investigate the effects of ezetimibe on lipid transport. Methods Rats were fed diets with and without ezetimibe (5.0 mg/kg), and their lymph was collected after feeding to quantify lymphatic lipid levels. Total cholesterol content in the intestinal mucosa was also measured. Results Rats that consumed ezetimibe had significantly lower lymphatic total cholesterol transport with the reduction of esterified cholesterol transport. According to the calculation based on cholesterol consumption, ezetimibe reduced the total cholesterol lymphatic recovery rate by 54 %. We also determined that ezetimibe significantly reduced the total cholesterol content in the intestinal mucosa. Conclusion This is the first direct evidence that ezetimibe inhibits esterified but not free cholesterol lymphatic transport in thoracic duct-cannulated rats. The results also indicate that ezetimibe is not involved in the lymphatic transport of triacylglycerols, phospholipids, or a-tocopherol.

UR - http://www.scopus.com/inward/record.url?scp=84867983066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867983066&partnerID=8YFLogxK

U2 - 10.1007/s10557-012-6403-3

DO - 10.1007/s10557-012-6403-3

M3 - Article

C2 - 22798197

AN - SCOPUS:84867983066

VL - 26

SP - 427

EP - 431

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 5

ER -